SPLENIC B-CELL LYMPHOMA/LEUKAEMIA WITH PROMINENT NUCLEOLI，SBLPN

Clinical trials for SPLENIC B-CELL LYMPHOMA/LEUKAEMIA WITH PROMINENT NUCLEOLI，SBLPN explained in plain language.

Never miss a new study

Get alerted when new SPLENIC B-CELL LYMPHOMA/LEUKAEMIA WITH PROMINENT NUCLEOLI，SBLPN trials appear

Sign up with your email to follow new studies for SPLENIC B-CELL LYMPHOMA/LEUKAEMIA WITH PROMINENT NUCLEOLI，SBLPN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for rare blood cancer: testing Triple-Drug attack

Disease control Recruiting now

This study is testing a new combination of three drugs—zanubrutinib, obinutuzumab, and lenalidomide—for people newly diagnosed with a rare blood cancer called SBLPN. The goal is to see if this three-drug approach is safe and effective at controlling the disease. Researchers will …

Matched conditions: SPLENIC B-CELL LYMPHOMA/LEUKAEMIA WITH PROMINENT NUCLEOLI，SBLPN

Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control

Last updated Mar 27, 2026 12:40 UTC

SPLENIC B-CELL LYMPHOMA/LEUKAEMIA WITH PROMINENT NUCLEOLI，SBLPN

Get alerted when new SPLENIC B-CELL LYMPHOMA/LEUKAEMIA WITH PROMINENT NUCLEOLI，SBLPN trials appear

New hope for rare blood cancer: testing Triple-Drug attack